secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K/A
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001628280-23-004835
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics FY2022 net loss $128.2M; cash runway to end 2024
----------------------------------------------------------------

- Revenue $31.1M in FY2022, down from $45.8M in FY2021 due to Roche agreement termination.
- Net loss $128.2M ($2.62/share) vs. $83.9M ($1.82/share) in FY2021; R&D spend rose to $117.8M.
- Cash, equivalents and marketable securities $337.1M at Dec 31, 2022, down from $451.5M.
- Phase 1 dose escalation data for CFT7455 (MM) and CFT8634 (synovial sarcoma) expected 2H 2023.
- IND submission for CFT8919 (EGFR L858R) on track for 1H 2023; CFT1946 trial dosing patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023004835/0001628280-23-004835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828023004835/cccc-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-004835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer